Summary

Patients with rheumatoid arthritis who did not have preexisting coronary artery disease and used methotrexate (MTX) for at least 24 months or a tumor necrosis factor (TNF) antagonist for at least 40 months were significantly less likely to develop cardiovascular disease than those who did not use MTX or anti -TNF therapy.